Akero Therapeutics Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
67
- Latest Deal Type
-
M&A
- Financing Rounds
-
11
Akero Therapeutics General Information
Description
Developer of biopharmaceuticals designed to treat serious metabolic diseases. The company's technology utilizes an engineered analog of fibroblast growth factor 21 to regulate lipid and carbohydrate metabolism, enabling patients with metabolic dysfunction-associated steatohepatitis to restore whole-body metabolic balance and reverse liver fibrosis.
Contact Information
Website
www.akerotx.com(Operating Subsidiary)
Corporate Office
- 601 Gateway Boulevard
- Suite 350
- South San Francisco, CA 94080
- United States
Corporate Office
- 601 Gateway Boulevard
- Suite 350
- South San Francisco, CA 94080
- United States
Akero Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Akero Therapeutics Comparisons
Industry
Financing
Details
Akero Therapeutics Competitors (71)
One of Akero Therapeutics’s 71 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Blade Therapeutics | Venture Capital-Backed | San Francisco, CA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Galectin Therapeutics | Corporation | Norcross, GA |
Akero Therapeutics Patents
Akero Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025155843-A1 | Method of treating liver or lung injury | Pending | 19-Jan-2024 | ||
| WO-2025123025-A1 | Plunger rod assembly configured to reduce use error associated with operation of a medical device including the plunger rod assembly | Inactive | 08-Dec-2023 | ||
| AU-2023343076-A1 | Fgf21 mutant polypeptides | Pending | 12-Sep-2022 | ||
| EP-4587458-A1 | Fgf21 mutant polypeptides | Pending | 12-Sep-2022 | ||
| WO-2024059507-A1 | Fgf21 mutant polypeptides | Inactive | 12-Sep-2022 | C07K14/50 |
Akero Therapeutics Signals
Akero Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Akero Therapeutics FAQs
-
When was Akero Therapeutics founded?
Akero Therapeutics was founded in 2017.
-
Where is Akero Therapeutics headquartered?
Akero Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Akero Therapeutics?
Akero Therapeutics has 67 total employees.
-
What industry is Akero Therapeutics in?
Akero Therapeutics’s primary industry is Drug Discovery.
-
Is Akero Therapeutics a private or public company?
Akero Therapeutics is a Private company.
-
What is the current valuation of Akero Therapeutics?
The current valuation of Akero Therapeutics is .
-
What is Akero Therapeutics’s current revenue?
The current revenue for Akero Therapeutics is .
-
How much funding has Akero Therapeutics raised over time?
Akero Therapeutics has raised $1.49B.
-
Who are Akero Therapeutics’s investors?
Adage Capital Management, Amgen, Apple Tree Partners (ATP), Atlas Venture, and Avidity Partners are 5 of 23 investors who have invested in Akero Therapeutics.
-
Who are Akero Therapeutics’s competitors?
NGM Biopharmaceuticals, Inovio Pharmaceuticals, Blade Therapeutics, Altimmune, and Galectin Therapeutics are some of the 71 competitors of Akero Therapeutics.
-
When was Akero Therapeutics acquired?
Akero Therapeutics was acquired on 09-Oct-2025.
-
Who acquired Akero Therapeutics?
Akero Therapeutics was acquired by Novo Nordisk.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process